Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS Lymphoma
Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to investigate the maximum tolerated dose and efficacy of
Orelabrutinib combined with Thiotepa in refractory and relapsed primary central nervous
system lymphoma (PCNSL).